SCHEMBL31260368

SCHEMBL31260368

CCCCC(CC)COC(=O)CCSc1ccc(C(C)=O)cc1O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.51
▸ TSHR P16473 3/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ ATM Q13315 1/20 0.51
▸ ALDH1A1 P00352 6/20 0.47
▸ MAPK1 P28482 3/20 0.47
▸ LMNA P02545 4/20 0.46
▸ HSD17B10 Q99714 1/20 0.45
▸ CA2 P00918 1/20 0.44
▸ PRSS1 P07477 1/20 0.42
▸ PRSS2 P07478 1/20 0.42
▸ PRSS3 P35030 1/20 0.42
▸ RECQL P46063 1/20 0.40
▸ LPAR3 Q9UBY5 3/20 0.34
▸ LPAR1 Q92633 2/20 0.34
▸ ENPP2 Q13822 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10239314 0.90 TSHR (0.49) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL10239252 0.88 TSHR (0.50) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL31644815 0.87 CYP3A4 (0.53) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL10239305 0.86 CYP3A4 (0.46) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL10239258 0.85 CYP3A4 (0.46) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL31260325 0.84 TSHR (0.50) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL2196924 0.83 CYP3A4 (0.51) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL31260359 0.82 CYP3A4 (0.48) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL21111957 0.82 TSHR (0.50) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL31260406 0.82 CYP3A4 (0.47) CYP3A4TSHRTDP1ATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4716685-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2026-04-01 — — EP disclosed
US-20260070906-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2026-03-12 — — US disclosed
WO-2024240726-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2024-11-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070906-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER TLR1, TLR6, TLR8 CYP3A4 3614/4885TSHR 1070/4885TDP1 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback